SCHEMBL16570187

SCHEMBL16570187

CS(=O)(=O)Nc1ccccc1Cn1ccc2cnc(Nc3ccc4c(c3)CCC(=O)N4CCO)nc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 14/20 0.48
▸ BRD4 O60885 9/20 0.48
▸ JAK3 P52333 5/20 0.41
▸ TYK2 P29597 3/20 0.41
▸ ALK Q9UM73 2/20 0.41
▸ AURKA O14965 1/20 0.41
▸ DCLK1 O15075 1/20 0.41
▸ PDPK1 O15530 1/20 0.41
▸ ROCK2 O75116 1/20 0.41
▸ PRKD3 O94806 1/20 0.41
▸ MAP4K4 O95819 1/20 0.41
▸ EGFR P00533 1/20 0.41
▸ NTRK1 P04629 1/20 0.41
▸ PRKCG P05129 1/20 0.41
▸ LCK P06239 1/20 0.41
▸ FYN P06241 1/20 0.41
▸ CDK1 P06493 1/20 0.41
▸ LYN P07948 1/20 0.41
▸ RET P07949 1/20 0.41
▸ IGF1R P08069 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16571036 0.91 JAK2 (0.46) JAK2BRD4JAK3TYK2ALK
SCHEMBL16570904 0.81 ULK1 (0.46) JAK2BRD4JAK3TYK2ALK
SCHEMBL16569928 0.79 PTK2 (0.57) JAK2JAK3TYK2ALKAURKA
SCHEMBL16571235 0.79 PTK2 (0.51) JAK2BRD4JAK3TYK2ALK
SCHEMBL16570032 0.75 PTK2 (0.59) JAK2BRD4JAK3TYK2ALK
SCHEMBL16570376 0.74 STAT6 (0.43) JAK2JAK3TYK2ALKAURKA
SCHEMBL16580996 0.73 STAT6 (0.61) JAK2BRD4JAK3EGFRFGFR1
SCHEMBL17971185 0.72 PTK2 (0.57) JAK2JAK3TYK2ALKAURKA
SCHEMBL16569985 0.71 PTK2 (0.57) JAK2JAK3TYK2ALKAURKA
SCHEMBL17958714 0.71 JAK2 (0.39) JAK2BRD4JAK3TYK2ALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2016-08-04 — — US claimed
WO-2015038417-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2015-03-19 — — WO claimed
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2016-08-04 — — US disclosed
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2016-08-04 — — US disclosed
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2016-08-04 — — US disclosed
WO-2015038417-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2015-03-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS SRC, PTK2, FYN JAK2 9/4885BRD4 427/4885JAK3 124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback